Baseline characteristics of patients with CLL and/or SLL treated with acalabrutinib or ibrutinib
. | Original sample . | ATT-weighted sample . | ||||
|---|---|---|---|---|---|---|
| Acalabrutinib cohort . | Ibrutinib cohort . | Std. diff. . | Acalabrutinib cohort . | Ibrutinib cohort . | Std. diff . | |
| n = 353 . | n = 2249 . | . | n = 353 . | n = 364 . | . | |
| Demographic characteristics | ||||||
| Age at index date, y | ||||||
| Mean ± SD | 71.9 ± 9.2 | 70.7 ± 9.5 | 0.130∗ | 71.9 ± 9.2 | 72.3 ± 3.8 | 0.049 |
| Median (IQR) | 73.0 (66.0-79.0) | 72.0 (65.0-79.0) | 73.0 (66.0-79.0) | 73.0 (66.0-80.0) | ||
| Female, n (%) | 136 (38.5) | 855 (38.0) | 0.011 | 136 (38.5) | 141 (38.7) | 0.004 |
| Race, n (%) | ||||||
| White | 271 (76.8) | 1659 (73.8) | 0.070 | 271 (76.8) | 287 (78.8) | 0.050 |
| Black or African American | 26 (7.4) | 198 (8.8) | 0.053 | 26 (7.4) | 24 (6.7) | 0.028 |
| Other race† | 25 (7.1) | 175 (7.8) | 0.027 | 25 (7.1) | 22 (6.0) | 0.044 |
| Asian | 7 (2.0) | 27 (1.2) | 0.063 | 7 (2.0) | 5 (1.5) | 0.038 |
| Unknown | 24 (6.8) | 190 (8.4) | 0.062 | 24 (6.8) | 26 (7.0) | 0.008 |
| Hispanic or Latino, n (%) | 9 (2.5) | 86 (3.8) | 0.073 | 9 (2.5) | 11 (2.9) | 0.021 |
| Geographic region, n (%) | ||||||
| South | 147 (41.6) | 887 (39.4) | 0.045 | 147 (41.6) | 147 (40.4) | 0.026 |
| Midwest | 55 (15.6) | 381 (16.9) | 0.037 | 55 (15.6) | 55 (15.1) | 0.013 |
| West | 69 (19.5) | 346 (15.4) | 0.110∗ | 69 (19.5) | 73 (19.9) | 0.010 |
| Northeast | 59 (16.7) | 488 (21.7) | 0.127∗ | 59 (16.7) | 60 (16.4) | 0.007 |
| Unknown | 23 (6.5) | 147 (6.5) | 0.001 | 23 (6.5) | 30 (8.2) | 0.063 |
| Year of index date, n (%) | ||||||
| 2018 | 19 (5.4) | 813 (36.1) | 0.820∗ | 19 (5.4) | 19 (5.2) | 0.009 |
| 2019 | 55 (15.6) | 913 (40.6) | 0.580∗ | 55 (15.6) | 54 (14.9) | 0.018 |
| 2020 | 247 (70.0) | 483 (21.5) | 1.114∗ | 247 (70.0) | 255 (69.8) | 0.003 |
| 2021 | 32 (9.1) | 40 (1.8) | 0.326∗ | 32 (9.1) | 37 (10.0) | 0.033 |
| Clinical characteristics | ||||||
| Year of diagnosis with CLL or SLL, n (%) | ||||||
| Before 2014 | 190 (53.8) | 1019 (45.3) | 0.171∗ | 190 (53.8) | 192 (52.8) | 0.021 |
| 2014 | 20 (5.7) | 178 (7.9) | 0.090 | 20 (5.7) | 20 (5.3) | 0.014 |
| 2015 | 31 (8.8) | 148 (6.6) | 0.083 | 31 (8.8) | 33 (9.1) | 0.010 |
| 2016 | 22 (6.2) | 185 (8.2) | 0.077 | 22 (6.2) | 25 (6.9) | 0.028 |
| 2017 | 19 (5.4) | 181 (8.0) | 0.107∗ | 19 (5.4) | 23 (6.2) | 0.035 |
| 2018 | 25 (7.1) | 263 (11.7) | 0.159∗ | 25 (7.1) | 27 (7.3) | 0.008 |
| 2019 | 22 (6.2) | 212 (9.4) | 0.119∗ | 22 (6.2) | 22 (6.0) | 0.011 |
| 2020 | 23 (6.5) | 61 (2.7) | 0.182∗ | 23 (6.5) | 23 (6.2) | 0.014 |
| 2021 | 1 (0.3) | 2 (0.1) | 0.045 | 1 (0.3) | 1 (0.3) | 0.002 |
| Time from diagnosis to index date, y | ||||||
| Mean ± SD | 7.7 ± 5.7 | 5.9 ± 5.8 | 0.308∗ | 7.7 ± 5.7 | 7.6 ± 2.6 | 0.021 |
| Median (IQR) | 7.0 (3.2-11.3) | 4.6 (1.4-8.6) | 7.0 (3.2-11.3) | 6.6 (3.1-10.2) | ||
| Line of therapy in which BTKi was received, n (%) | ||||||
| 1L | 67 (19.0) | 1211 (53.8) | 0.777∗ | 67 (19.0) | 66 (18.1) | 0.024 |
| 2L | 140 (39.7) | 714 (31.7) | 0.166∗ | 140 (39.7) | 141 (38.6) | 0.022 |
| 3L+ | 146 (41.4) | 324 (14.4) | 0.630∗ | 146 (41.4) | 158 (43.4) | 0.041 |
| Rai stage at diagnosis, n (%) | ||||||
| Stage 0 | 80 (22.7) | 533 (23.7) | 0.025 | 80 (22.7) | 92 (25.3) | 0.061 |
| Stage I | 49 (13.9) | 335 (14.9) | 0.029 | 49 (13.9) | 48 (13.1) | 0.022 |
| Stage II | 30 (8.5) | 147 (6.5) | 0.075 | 30 (8.5) | 28 (7.8) | 0.026 |
| Stage III | 20 (5.7) | 109 (4.8) | 0.037 | 20 (5.7) | 19 (5.1) | 0.026 |
| Stage IV | 32 (9.1) | 172 (7.6) | 0.051 | 32 (9.1) | 33 (9.2) | 0.004 |
| Unknown | 142 (40.2) | 953 (42.4) | 0.044 | 142 (40.2) | 144 (39.5) | 0.014 |
| Modified Quan-CCI score | ||||||
| Mean ± SD | 0.1 ± 0.4 | 0.1 ± 0.4 | 0.008 | 0.1 ± 0.4 | 0.1 ± 0.1 | 0.017 |
| Median (IQR) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | ||
| Cardiovascular risk factors, n (%) | ||||||
| Hypertension | 23 (6.5) | 220 (9.8) | 0.120∗ | 23 (6.5) | 30 (8.4) | 0.070 |
| Atrial fibrillation | 12 (3.4) | 36 (1.6) | 0.115∗ | 12 (3.4) | 17 (4.7) | 0.067 |
| Hypercholesterolemia | 14 (4.0) | 176 (7.8) | 0.164∗ | 14 (4.0) | 25 (6.7) | 0.123 |
| Congestive heart failure | 4 (1.1) | 19 (0.8) | 0.029 | 4 (1.1) | 4 (1.1) | 0.007 |
| Peripheral arterial disease | 1 (0.3) | 13 (0.6) | 0.045 | 1 (0.3) | 7 (2.0) | 0.162 |
| Cerebrovascular disease | 0 (0.0) | 13 (0.6) | 0.108 | 0 (0.0) | 2 (0.7) | 0.116 |
| Diabetes | 11 (3.1) | 88 (3.9) | 0.043 | 11 (3.1) | 14 (3.7) | 0.035 |
| Myocardial infarction | 1 (0.3) | 7 (0.3) | 0.005 | 1 (0.3) | 0 (0.1) | 0.053 |
| ECOG performance status, n (%) | ||||||
| 0 | 129 (36.5) | 897 (39.9) | 0.069 | 129 (36.5) | 127 (34.8) | 0.037 |
| 1 | 128 (36.3) | 661 (29.4) | 0.147∗ | 128 (36.3) | 136 (37.3) | 0.022 |
| 2+ | 40 (11.3) | 211 (9.4) | 0.064 | 40 (11.3) | 43 (11.8) | 0.014 |
| Unknown | 56 (15.9) | 480 (21.3) | 0.141∗ | 56 (15.9) | 59 (16.1) | 0.008 |
| Baseline medications, n (%) | ||||||
| Prior BTKi use | 121 (34.3) | 55 (2.4) | 0.902∗ | 121 (34.3) | 25 (6.7) | 0.726∗ |
| Anticoagulants | 3 (0.8) | 13 (0.6) | 0.032 | 3 (0.8) | 5 (1.4) | 0.055 |
| Antiplatelets | 1 (0.3) | 6 (0.3) | 0.003 | 1 (0.3) | 1 (0.1) | 0.032 |
| CYP3A inhibitors | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | 0 (0.0) | - |
| CYP3A inducers | 0 (0.0) | 1 (0.0) | 0.030 | 0 (0.0) | 2 (0.7) | 0.117∗ |
. | Original sample . | ATT-weighted sample . | ||||
|---|---|---|---|---|---|---|
| Acalabrutinib cohort . | Ibrutinib cohort . | Std. diff. . | Acalabrutinib cohort . | Ibrutinib cohort . | Std. diff . | |
| n = 353 . | n = 2249 . | . | n = 353 . | n = 364 . | . | |
| Demographic characteristics | ||||||
| Age at index date, y | ||||||
| Mean ± SD | 71.9 ± 9.2 | 70.7 ± 9.5 | 0.130∗ | 71.9 ± 9.2 | 72.3 ± 3.8 | 0.049 |
| Median (IQR) | 73.0 (66.0-79.0) | 72.0 (65.0-79.0) | 73.0 (66.0-79.0) | 73.0 (66.0-80.0) | ||
| Female, n (%) | 136 (38.5) | 855 (38.0) | 0.011 | 136 (38.5) | 141 (38.7) | 0.004 |
| Race, n (%) | ||||||
| White | 271 (76.8) | 1659 (73.8) | 0.070 | 271 (76.8) | 287 (78.8) | 0.050 |
| Black or African American | 26 (7.4) | 198 (8.8) | 0.053 | 26 (7.4) | 24 (6.7) | 0.028 |
| Other race† | 25 (7.1) | 175 (7.8) | 0.027 | 25 (7.1) | 22 (6.0) | 0.044 |
| Asian | 7 (2.0) | 27 (1.2) | 0.063 | 7 (2.0) | 5 (1.5) | 0.038 |
| Unknown | 24 (6.8) | 190 (8.4) | 0.062 | 24 (6.8) | 26 (7.0) | 0.008 |
| Hispanic or Latino, n (%) | 9 (2.5) | 86 (3.8) | 0.073 | 9 (2.5) | 11 (2.9) | 0.021 |
| Geographic region, n (%) | ||||||
| South | 147 (41.6) | 887 (39.4) | 0.045 | 147 (41.6) | 147 (40.4) | 0.026 |
| Midwest | 55 (15.6) | 381 (16.9) | 0.037 | 55 (15.6) | 55 (15.1) | 0.013 |
| West | 69 (19.5) | 346 (15.4) | 0.110∗ | 69 (19.5) | 73 (19.9) | 0.010 |
| Northeast | 59 (16.7) | 488 (21.7) | 0.127∗ | 59 (16.7) | 60 (16.4) | 0.007 |
| Unknown | 23 (6.5) | 147 (6.5) | 0.001 | 23 (6.5) | 30 (8.2) | 0.063 |
| Year of index date, n (%) | ||||||
| 2018 | 19 (5.4) | 813 (36.1) | 0.820∗ | 19 (5.4) | 19 (5.2) | 0.009 |
| 2019 | 55 (15.6) | 913 (40.6) | 0.580∗ | 55 (15.6) | 54 (14.9) | 0.018 |
| 2020 | 247 (70.0) | 483 (21.5) | 1.114∗ | 247 (70.0) | 255 (69.8) | 0.003 |
| 2021 | 32 (9.1) | 40 (1.8) | 0.326∗ | 32 (9.1) | 37 (10.0) | 0.033 |
| Clinical characteristics | ||||||
| Year of diagnosis with CLL or SLL, n (%) | ||||||
| Before 2014 | 190 (53.8) | 1019 (45.3) | 0.171∗ | 190 (53.8) | 192 (52.8) | 0.021 |
| 2014 | 20 (5.7) | 178 (7.9) | 0.090 | 20 (5.7) | 20 (5.3) | 0.014 |
| 2015 | 31 (8.8) | 148 (6.6) | 0.083 | 31 (8.8) | 33 (9.1) | 0.010 |
| 2016 | 22 (6.2) | 185 (8.2) | 0.077 | 22 (6.2) | 25 (6.9) | 0.028 |
| 2017 | 19 (5.4) | 181 (8.0) | 0.107∗ | 19 (5.4) | 23 (6.2) | 0.035 |
| 2018 | 25 (7.1) | 263 (11.7) | 0.159∗ | 25 (7.1) | 27 (7.3) | 0.008 |
| 2019 | 22 (6.2) | 212 (9.4) | 0.119∗ | 22 (6.2) | 22 (6.0) | 0.011 |
| 2020 | 23 (6.5) | 61 (2.7) | 0.182∗ | 23 (6.5) | 23 (6.2) | 0.014 |
| 2021 | 1 (0.3) | 2 (0.1) | 0.045 | 1 (0.3) | 1 (0.3) | 0.002 |
| Time from diagnosis to index date, y | ||||||
| Mean ± SD | 7.7 ± 5.7 | 5.9 ± 5.8 | 0.308∗ | 7.7 ± 5.7 | 7.6 ± 2.6 | 0.021 |
| Median (IQR) | 7.0 (3.2-11.3) | 4.6 (1.4-8.6) | 7.0 (3.2-11.3) | 6.6 (3.1-10.2) | ||
| Line of therapy in which BTKi was received, n (%) | ||||||
| 1L | 67 (19.0) | 1211 (53.8) | 0.777∗ | 67 (19.0) | 66 (18.1) | 0.024 |
| 2L | 140 (39.7) | 714 (31.7) | 0.166∗ | 140 (39.7) | 141 (38.6) | 0.022 |
| 3L+ | 146 (41.4) | 324 (14.4) | 0.630∗ | 146 (41.4) | 158 (43.4) | 0.041 |
| Rai stage at diagnosis, n (%) | ||||||
| Stage 0 | 80 (22.7) | 533 (23.7) | 0.025 | 80 (22.7) | 92 (25.3) | 0.061 |
| Stage I | 49 (13.9) | 335 (14.9) | 0.029 | 49 (13.9) | 48 (13.1) | 0.022 |
| Stage II | 30 (8.5) | 147 (6.5) | 0.075 | 30 (8.5) | 28 (7.8) | 0.026 |
| Stage III | 20 (5.7) | 109 (4.8) | 0.037 | 20 (5.7) | 19 (5.1) | 0.026 |
| Stage IV | 32 (9.1) | 172 (7.6) | 0.051 | 32 (9.1) | 33 (9.2) | 0.004 |
| Unknown | 142 (40.2) | 953 (42.4) | 0.044 | 142 (40.2) | 144 (39.5) | 0.014 |
| Modified Quan-CCI score | ||||||
| Mean ± SD | 0.1 ± 0.4 | 0.1 ± 0.4 | 0.008 | 0.1 ± 0.4 | 0.1 ± 0.1 | 0.017 |
| Median (IQR) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | ||
| Cardiovascular risk factors, n (%) | ||||||
| Hypertension | 23 (6.5) | 220 (9.8) | 0.120∗ | 23 (6.5) | 30 (8.4) | 0.070 |
| Atrial fibrillation | 12 (3.4) | 36 (1.6) | 0.115∗ | 12 (3.4) | 17 (4.7) | 0.067 |
| Hypercholesterolemia | 14 (4.0) | 176 (7.8) | 0.164∗ | 14 (4.0) | 25 (6.7) | 0.123 |
| Congestive heart failure | 4 (1.1) | 19 (0.8) | 0.029 | 4 (1.1) | 4 (1.1) | 0.007 |
| Peripheral arterial disease | 1 (0.3) | 13 (0.6) | 0.045 | 1 (0.3) | 7 (2.0) | 0.162 |
| Cerebrovascular disease | 0 (0.0) | 13 (0.6) | 0.108 | 0 (0.0) | 2 (0.7) | 0.116 |
| Diabetes | 11 (3.1) | 88 (3.9) | 0.043 | 11 (3.1) | 14 (3.7) | 0.035 |
| Myocardial infarction | 1 (0.3) | 7 (0.3) | 0.005 | 1 (0.3) | 0 (0.1) | 0.053 |
| ECOG performance status, n (%) | ||||||
| 0 | 129 (36.5) | 897 (39.9) | 0.069 | 129 (36.5) | 127 (34.8) | 0.037 |
| 1 | 128 (36.3) | 661 (29.4) | 0.147∗ | 128 (36.3) | 136 (37.3) | 0.022 |
| 2+ | 40 (11.3) | 211 (9.4) | 0.064 | 40 (11.3) | 43 (11.8) | 0.014 |
| Unknown | 56 (15.9) | 480 (21.3) | 0.141∗ | 56 (15.9) | 59 (16.1) | 0.008 |
| Baseline medications, n (%) | ||||||
| Prior BTKi use | 121 (34.3) | 55 (2.4) | 0.902∗ | 121 (34.3) | 25 (6.7) | 0.726∗ |
| Anticoagulants | 3 (0.8) | 13 (0.6) | 0.032 | 3 (0.8) | 5 (1.4) | 0.055 |
| Antiplatelets | 1 (0.3) | 6 (0.3) | 0.003 | 1 (0.3) | 1 (0.1) | 0.032 |
| CYP3A inhibitors | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | 0 (0.0) | - |
| CYP3A inducers | 0 (0.0) | 1 (0.0) | 0.030 | 0 (0.0) | 2 (0.7) | 0.117∗ |